Open AccessProgrammed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Author(s) -
Katrien Clotman,
Katleen Janssens,
Pol Specenier,
Ilse Weets,
Christophe De Block
Publication year - 2018
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2018-00728
Subject(s) - pembrolizumab , medicine , nivolumab , diabetic ketoacidosis , ipilimumab , type 1 diabetes , diabetes mellitus , immunotherapy , adverse effect , ketoacidosis , oncology , immunology , cancer , endocrinology
Pembrolizumab (Keytruda; Merck Sharp & Dohme) is a humanized IgG4 monoclonal antibody used in cancer immunotherapy. It targets the programmed cell death-1 (PD-1) receptor, which is important in maintaining self-tolerance. However, immune checkpoint blockade is associated with a risk for immune-related adverse events (irAEs) potentially affecting the endocrine organs. Type 1 diabetes mellitus is a rare irAE of PD-1 inhibitors, occurring in 0.2% of cases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom